Every day in India, countless individuals living with well-managed diabetes experience sudden, devastating vision loss completely unnecessarily. The tragedy of diabetic retinopathy is not a lack of viable medical solutions, but a lack of early, proactive detection; the microscopic vascular damage caused by chronic high blood glucose progresses silently, destroying delicate ocular tissue without causing a single warning symptom until advanced stages.
As a primary cause of preventable blindness in working-age adults, this microvascular condition demands a dual-front clinical defense. Successfully preserving your sight requires combining high-precision localized treatments such as advanced anti-VEGF intravitreal injections, non-invasive laser photocoagulation, or specialized vitrectomy surgery with aggressive, long-term systemic control of your HbA1c levels. This comprehensive guide breaks down how diabetes alters retinal anatomy, details the four major stages of disease progression, and explains why securing a coordinated care plan with the best diabetologist in Chennai at Dr. Humayun Speciality Hospital is the most decisive action you can take to safeguard your vision.
The Vision Loss That Does Not Have to Happen
Diabetic retinopathy is the leading cause of preventable vision impairment in the working-age population globally. As confirmed by a comprehensive review published in the Journal of Clinical Medicine, laser photocoagulation is essential in treating DR in conjunction with anti-vascular endothelial growth factor injection, steroids, and vitrectomy. These interventions exist. They work. And they work best when used early.
The critical word in every discussion of diabetic retinopathy is "preventable." The retinal damage caused by diabetes does not become irreversible immediately. It progresses through stages, and there is a window, specific to each stage, in which treatment can halt progression and preserve vision. When that window is identified and treatment delivered, vision loss can be prevented or significantly reduced. When that window passes, treatment can still stabilise the condition, but vision already lost cannot be restored.
India carries the second largest diabetes burden globally. In Tamil Nadu, urban prevalence of Type 2 diabetes has been rising steadily, and a significant proportion of those living with diabetes are unaware of retinal involvement because the early stages of diabetic retinopathy cause no symptoms whatsoever. This silent progression is the central clinical challenge: by the time the patient notices vision problems, the disease has already advanced.
How Diabetes Damages the Retina
The retina is the light-sensitive layer at the back of the eye that converts visual images into signals sent to the brain. It is supplied by a dense network of tiny capillaries. Chronically elevated blood glucose damages these capillaries through a series of biochemical mechanisms: it causes thickening and weakening of the capillary walls, promotes inflammation, increases the production of a protein called VEGF (vascular endothelial growth factor), and impairs the pericyte cells that regulate capillary integrity.
The result is a cascade of structural damage. Weakened capillary walls leak fluid and blood (haemorrhages) into the retina. Blocked capillaries leave areas of the retina without adequate blood supply (ischaemia). In response to ischaemia, the eye attempts to grow new blood vessels (neovascularisation), stimulated by excess VEGF. However, these new vessels are structurally fragile and prone to bleeding, and they grow on the surface of the retina and into the vitreous gel, causing vision-threatening complications.
Understanding this mechanism explains why every major treatment for diabetic retinopathy targets one or more of these specific pathways: controlling blood sugar addresses the root cause, anti-VEGF injections block the VEGF protein driving abnormal vessel growth, laser therapy reduces retinal oxygen demand and destroys leaking vessels, and surgery addresses the mechanical consequences of advanced disease.
The 4 Stages of Diabetic Retinopathy
Staging diabetic retinopathy determines the urgency and type of treatment required. The international classification uses four stages:
-
Stage 1: Mild Non-Proliferative Diabetic Retinopathy (NPDR) Microaneurysms (small bulges in capillary walls) are the earliest visible sign, detectable only on dilated retinal examination. No symptoms. Vision is unaffected. Management is intensive glycaemic and blood pressure control with annual retinal screening.
-
Stage 2: Moderate NPDR More widespread haemorrhages, hard exudates (cholesterol deposits from leaking vessels), and cotton-wool spots (signs of localised ischaemia) appear. Still typically asymptomatic. Glycaemic control remains central, with screening frequency increased to every 6 months.
-
Stage 3: Severe NPDR Extensive haemorrhages across all four quadrants of the retina, or significant venous beading, or significant microvascular abnormalities. The risk of progression to proliferative disease within one year is approximately 50%. This stage requires close monitoring and often treatment initiation.
-
Stage 4: Proliferative Diabetic Retinopathy (PDR) Neovascularisation (new, fragile blood vessels) has developed on the retinal surface or optic disc. These vessels bleed easily, causing vitreous haemorrhage, and can cause tractional retinal detachment by forming fibrovascular membranes. This is the most vision-threatening stage and requires prompt treatment.
-
Diabetic Macular Edema (DME) can occur at any stage and is the most common cause of vision loss in diabetic retinopathy. It occurs when fluid leaks into the macula, the central part of the retina responsible for sharp, detailed vision, causing blurring and distortion of central sight.
Diabetic Macular Edema: Central Vision at Risk
As Stanford Health Care describes, anti-VEGF medicines slow the growth of abnormal blood vessels in the retina and are the primary treatment for diabetic macular edema.
DME deserves separate attention because it is the most common reason people with diabetic retinopathy experience reduced vision, and it can develop even in the earlier, non-proliferative stages where the general retinal picture appears relatively controlled. A patient with Moderate NPDR and clinically significant DME requires treatment for the oedema urgently, regardless of the overall stage.
Symptoms of DME include blurred or distorted central vision, difficulty reading or recognising faces, and colours appearing washed out or faded. Because the peripheral retina remains functional, patients may not notice DME until it has been present and causing damage for months. Regular optical coherence tomography (OCT) at retinal check-ups detects macular thickening before it becomes symptomatic.
Diabetic Retinopathy Treatment 1: Controlling Blood Sugar and Blood Pressure
The most important and most undervalued diabetic retinopathy treatment is the one that does not involve an eye specialist at all. Intensive glycaemic control (maintaining HbA1c below 7%) and blood pressure control (below 130/80 mmHg) are the most powerful interventions available for preventing retinopathy from developing and slowing its progression in those who already have it.
Multiple landmark clinical trials including the DCCT (Type 1 diabetes) and UKPDS (Type 2 diabetes) demonstrated unequivocally that intensive blood sugar control reduces the risk of developing retinopathy by 76% and slows its progression by 54% in people with existing disease.
In practical terms, this means that the best diabetologist in Chennai is not a peripheral figure in retinopathy management. They are central to it. Every percentage point reduction in HbA1c produces a measurable reduction in retinopathy progression. Every millimetre of mercury reduction in blood pressure reduces the risk of retinopathy worsening. The ophthalmologist and the diabetologist must work together, with shared information about disease stage and treatment response, to achieve the outcomes that matter: preserving the patient's vision.
This is why coordinated multidisciplinary care is the standard of practice for diabetic retinopathy, not an optional extra. When the endocrinologist optimising blood sugar and the ophthalmologist managing the retinal changes work from the same clinical picture, treatment decisions at both ends of the care are better informed.
Diabetic Retinopathy Treatment 2: Anti-VEGF Intravitreal Injections
Anti-VEGF (anti-vascular endothelial growth factor) intravitreal injections are now the primary treatment for both diabetic macular edema and proliferative diabetic retinopathy, representing the most significant advance in retinal medicine over the past two decades.
VEGF is the protein that drives abnormal blood vessel growth in the diabetic retina. Anti-VEGF medications block the VEGF receptor, suppressing both new vessel formation and the leakage from existing abnormal vessels. The result is reduction of macular oedema, regression of neovascularisation, and in many cases, measurable improvement in visual acuity rather than simply stabilisation.
As confirmed by Wills Eye Hospital, the injections are performed in an office setting using topical anaesthetic eye drops, are very well tolerated, and complications are rare.
Currently approved anti-VEGF agents include:
-
Ranibizumab (Lucentis): Extensively validated in landmark DRCR.net trials. Expanded approval in 2017 for all forms of diabetic retinopathy, with or without DME. In February 2025, the FDA approved a sustained-release intravitreal ranibizumab implant (Susvimo), providing continuous drug delivery without repeated monthly injections.
-
Aflibercept (Eylea): Approved for DME and PDR, with a slightly longer dosing interval between injections compared to ranibizumab in some patients.
-
Faricimab (Vabysmo): A newer bispecific antibody targeting both VEGF and Ang-2, with evidence for extended dosing intervals in DME.
-
Bevacizumab (Avastin): Widely used off-label in India due to significantly lower cost, with comparative effectiveness data supporting its use for DME.
Treatment typically begins with monthly loading injections for 3 to 6 months, followed by a treat-and-extend or pro-re-nata (as-needed) protocol based on retinal response assessed at each visit by OCT imaging.
Diabetic Retinopathy Treatment 3: Laser Photocoagulation
Laser therapy has been a cornerstone of diabetic retinopathy treatment for over five decades and remains highly relevant in current practice, both as a primary treatment and in combination with anti-VEGF therapy.
Two distinct laser techniques are used for different indications:
Focal and Grid Laser for Diabetic Macular Edema
Focal laser applies precise burns to individual leaking microaneurysms in the macula. Grid laser applies a pattern of burns to areas of diffuse leakage. As Wills Eye Hospital confirms, focal laser is performed in one session, is generally painless, and can take up to 2 to 3 months to see any therapeutic effect.
In current practice, laser for DME is often used after anti-VEGF injections when the response is incomplete, or in specific subtypes of DME where focal leakage from microaneurysms is the dominant mechanism.
Panretinal Photocoagulation (PRP) for Proliferative Retinopathy
PRP involves creating 1,000 to 2,000 small laser burns across the peripheral retina. The mechanism is counterintuitive but effective: by destroying peripheral retinal tissue, PRP reduces the retina's overall oxygen demand, suppressing the ischaemic drive that stimulates VEGF production and neovascularisation.
As the National Eye Institute confirms, scatter laser surgery works best before the new, fragile blood vessels have started to bleed. PRP reduces the risk of severe vision loss from proliferative diabetic retinopathy by approximately 50%.
December 2024 NICE guidelines reaffirmed the central role of both panretinal photocoagulation for PDR and macular laser for DMO, confirming that laser remains an essential component of the diabetic retinopathy treatment toolkit.
Diabetic Retinopathy Treatment 4: Intravitreal Corticosteroids
Corticosteroids delivered directly into the vitreous cavity address the inflammatory component of diabetic macular edema. They reduce vascular permeability and suppress inflammatory mediators that contribute to fluid accumulation in the macula.
Triamcinolone acetonide injected intravitreally reduces macular thickness and improves visual acuity in DME, with effects lasting 2 to 3 months before repeat injection is needed.
Dexamethasone intravitreal implant (Ozurdex): A biodegradable implant releasing dexamethasone over approximately 3 to 6 months. Particularly useful for DME in patients with pseudophakic eyes (those who have had cataract surgery) where cataract formation from steroid is not a concern.
Intravitreal corticosteroids carry risks of elevated intraocular pressure (leading to glaucoma) and cataract formation that require monitoring. They are typically used when anti-VEGF injections have not achieved adequate macular response, when the patient cannot attend for frequent injections, or when anti-VEGF is contraindicated.
Diabetic Retinopathy Treatment 5: Vitrectomy Surgery
Vitrectomy is surgical removal of the vitreous gel from the eye, performed when advanced diabetic retinopathy has produced complications that cannot be managed with injections or laser alone.
Indications for vitrectomy include:
Vitreous haemorrhage that does not clear spontaneously. When proliferative vessels on the retina bleed into the vitreous, the patient experiences sudden, dramatic vision loss. Most vitreous haemorrhages are given time to clear spontaneously. As confirmed by the Diabetic Retinopathy Vitrectomy Study, vitrectomy is advisable for eyes with vitreous haemorrhage that fails to resolve spontaneously within 6 months.
Tractional retinal detachment occurring when fibrovascular membranes on the retinal surface contract and pull the retina away from its support layer. This is a vision emergency requiring urgent vitrectomy to release the traction and reattach the retina before the macula detaches.
Non-resolving diabetic macular edema in specific cases where the vitreous is adherent to the macula and contributing to the oedema.
The procedure is performed under local or general anaesthesia in an operating theatre. Small instruments are inserted through tiny incisions in the eye wall. The vitreous is removed, traction-forming membranes are carefully peeled, and laser photocoagulation is often delivered internally during the procedure. A gas bubble or silicone oil may be placed to maintain retinal position when retinal detachment has occurred.
Why the Best Diabetologist in Chennai Is Central to Eye Health
The connection between diabetes management and retinopathy outcomes is direct, quantifiable, and often underestimated by both patients and healthcare providers.
Every clinic visit where HbA1c is reviewed and optimised is a retinopathy intervention. Every blood pressure reading adjusted and controlled is preventing further microvascular damage to the retinal capillaries. Every discussion about diet, exercise, and medication adherence is protecting the macula.
The best diabetologist in Chennai is therefore not a peripheral figure in the retinopathy story. They are co-authors of the visual outcome. A diabetologist who screens for retinopathy at diagnosis, ensures annual dilated eye examinations happen, communicates with the ophthalmologist when retinopathy is identified, and prioritises HbA1c control with the awareness that the patient's vision is at stake, provides a level of integrated care that changes outcomes measurably.
At Dr. Humayun Speciality Hospital, the diabetology team understands that managing Type 2 diabetes is not simply about blood sugar numbers. It is about protecting the eyes, kidneys, heart, and nerves from the microvascular and macrovascular damage that uncontrolled diabetes causes over time. The diabetologist and ophthalmologist at the hospital work in coordination, ensuring that retinal screening is part of every diabetic patient's care plan, and that when retinopathy is identified, escalation to treatment is prompt.
Comprehensive Diabetic Eye and Diabetes Care at Dr. Humayun Speciality Hospital, T. Nagar, Chennai At Dr. Humayun Speciality Hospital, diabetic retinopathy is managed through a coordinated approach that connects diabetology and ophthalmology care within the same clinical environment.
Services include:
-
Annual dilated retinal examination for all patients with diabetes, with OCT imaging for detection of diabetic macular edema before it becomes symptomatic.
-
Retinal photography and fluorescein angiography for detailed documentation and staging of diabetic retinopathy.
-
Intravitreal anti-VEGF injection for diabetic macular edema and proliferative retinopathy, with structured injection protocols and response monitoring by OCT at each visit.
-
Laser photocoagulation including focal, grid, and panretinal photocoagulation, performed by experienced retinal specialists.
-
Intravitreal corticosteroid therapy for steroid-responsive DME and cases requiring extended treatment intervals.
-
Vitreoretinal surgery including vitrectomy for vitreous haemorrhage, tractional retinal detachment, and advanced proliferative disease.
-
Coordinated diabetology care with HbA1c optimisation, blood pressure management, and medication review integrated with retinal care planning.
Conclusion
Diabetic retinopathy treatment is most effective when applied early. The vision you protect today cannot be restored once it is lost. An annual retinal examination is the most important appointment any person with diabetes can keep.
Have diabetes and not had a retinal examination in the past year?
Chat with our medical care assistant for quick guidance and support and book a diabetic eye assessment at Dr. Humayun Speciality Hospital, T. Nagar, Chennai.
Dr. Humayun Speciality Hospital New No. 10, Chevalier Sivaji Ganesan Road, S W Boag Road, T. Nagar, Chennai, 600017
